Basically the market priced the stock at ~ cash on hand at the time of closing, considered the JNCE IP to be worthless, and therefore CVR to be distributed to existing shareholders tied to certain clinical stage IP to be worthless? Gilead could pick up the remaining trial drugs for a song?
JNCE isn't a highly followed stock. Once more people see this news, we'll move higher. Should be a healthy jump tomorrow.$Jounce Therapeutics Inc.(JNCE)$
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments